JP2019508370A5 - - Google Patents

Download PDF

Info

Publication number
JP2019508370A5
JP2019508370A5 JP2018532465A JP2018532465A JP2019508370A5 JP 2019508370 A5 JP2019508370 A5 JP 2019508370A5 JP 2018532465 A JP2018532465 A JP 2018532465A JP 2018532465 A JP2018532465 A JP 2018532465A JP 2019508370 A5 JP2019508370 A5 JP 2019508370A5
Authority
JP
Japan
Prior art keywords
patient
ccl20
level
disease
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018532465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508370A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/067120 external-priority patent/WO2017112536A1/en
Publication of JP2019508370A publication Critical patent/JP2019508370A/ja
Publication of JP2019508370A5 publication Critical patent/JP2019508370A5/ja
Priority to JP2021172872A priority Critical patent/JP2022031643A/ja
Pending legal-status Critical Current

Links

JP2018532465A 2015-12-22 2016-12-16 Il23アンタゴニストに対する臨床応答の予測因子としてのccl20 Pending JP2019508370A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021172872A JP2022031643A (ja) 2015-12-22 2021-10-22 Il23アンタゴニストに対する臨床応答の予測因子としてのccl20

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562271156P 2015-12-22 2015-12-22
US62/271,156 2015-12-22
PCT/US2016/067120 WO2017112536A1 (en) 2015-12-22 2016-12-16 Ccl20 as a predictor of clinical response to il23-antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021172872A Division JP2022031643A (ja) 2015-12-22 2021-10-22 Il23アンタゴニストに対する臨床応答の予測因子としてのccl20

Publications (2)

Publication Number Publication Date
JP2019508370A JP2019508370A (ja) 2019-03-28
JP2019508370A5 true JP2019508370A5 (cg-RX-API-DMAC7.html) 2020-06-25

Family

ID=59091179

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018532465A Pending JP2019508370A (ja) 2015-12-22 2016-12-16 Il23アンタゴニストに対する臨床応答の予測因子としてのccl20
JP2021172872A Pending JP2022031643A (ja) 2015-12-22 2021-10-22 Il23アンタゴニストに対する臨床応答の予測因子としてのccl20

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021172872A Pending JP2022031643A (ja) 2015-12-22 2021-10-22 Il23アンタゴニストに対する臨床応答の予測因子としてのccl20

Country Status (12)

Country Link
US (2) US11220541B2 (cg-RX-API-DMAC7.html)
EP (1) EP3393515A4 (cg-RX-API-DMAC7.html)
JP (2) JP2019508370A (cg-RX-API-DMAC7.html)
KR (1) KR20180096633A (cg-RX-API-DMAC7.html)
CN (1) CN108472367A (cg-RX-API-DMAC7.html)
AU (1) AU2016379157A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018012626A2 (cg-RX-API-DMAC7.html)
CA (1) CA3007098A1 (cg-RX-API-DMAC7.html)
IL (1) IL259704A (cg-RX-API-DMAC7.html)
MX (1) MX2018007589A (cg-RX-API-DMAC7.html)
RU (1) RU2018124603A (cg-RX-API-DMAC7.html)
WO (1) WO2017112536A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
MX2018003376A (es) 2015-09-17 2018-08-15 Amgen Inc Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23.
HUE063462T2 (hu) 2018-09-24 2024-01-28 Janssen Biotech Inc A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel
CN108957014A (zh) * 2018-09-27 2018-12-07 郑州大学第附属医院 结直肠癌血清标志物、表达评估方法、试剂盒及应用
EP3946592A4 (en) * 2019-03-26 2023-01-04 Astrazeneca Collaboration Ventures, LLC PATIENT POPULATIONS LIKELY TO BENEFIT FROM IL23 ANTAGONIST THERAPY
KR20230165746A (ko) 2020-11-30 2023-12-05 민데라 코포레이션 마이크로니들 디바이스 및 방법, 및 피부 병태 어세이
CN113092652B (zh) * 2021-03-19 2022-09-30 浙江工商大学 一种用于评估个体过敏程度的试剂盒
CN114113630B (zh) * 2021-11-24 2023-07-28 中南大学湘雅医院 Serpinb3/b4作为靶点在玫瑰痤疮等炎症性皮肤病治疗药物中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8318754D0 (en) 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5455160A (en) 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
DE69731103T2 (de) 1996-11-01 2005-11-17 Fagerhol, Magne K., Dr. Verfahren zur proteinextraktion
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
EP1756138A4 (en) 2004-03-05 2009-07-01 Archemix Corp APTAMERS FACILITATED TO THE FAMILY OF HUMAN IL-12 CYTOKINS AND THEIR USE AS THERAPEUTICS AGAINST AUTOIMMUNE DISEASES
CA2565701A1 (en) 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
KR100681763B1 (ko) 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
CA2613818C (en) 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
SI1937721T1 (sl) 2005-08-25 2010-11-30 Lilly Co Eli Anti il protitelesa
ME02705B (me) 2005-08-31 2017-10-20 Merck Sharp & Dohme Inženjerisana anti-il-23 antitela
JP2009518314A (ja) 2005-12-02 2009-05-07 ジェネンテック・インコーポレーテッド Il−22に結合する抗体およびil−22rに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
WO2007098065A2 (en) 2006-02-17 2007-08-30 The United States Of America As Represented By The Department Of Veterans Affairs Human sodium channel isoforms
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス, インコーポレイテッド Il−17およびil−23アンタゴニストならびにその使用方法
CN103396489A (zh) 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
HUE042172T2 (hu) 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
KR20100124326A (ko) 2008-03-14 2010-11-26 엑사젠 다이어그노스틱스, 인코포레이티드 염증성 장 질병 및 과민성 장 증후군에 대한 생체마커
WO2010027766A1 (en) 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
US20100221752A2 (en) 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
EP2347256A4 (en) 2008-10-09 2012-02-08 Alfagene Bioscience Inc USE AND IDENTIFY BIOMARKERS FOR STOMACH DISEASES
EP2352762A1 (en) 2008-11-03 2011-08-10 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
WO2010115786A1 (en) 2009-04-01 2010-10-14 Glaxo Group Limited Anti-il-23 immunoglobulins
WO2010129964A1 (en) 2009-05-08 2010-11-11 The Board Of Trustees Of The University Of Illinois Drug targets for prevention of arrhythmia in heart disease
WO2010142534A1 (en) 2009-05-27 2010-12-16 Ablynx Nv Biparatopic protein constructs directed against il-23
ES2509616T3 (es) 2009-06-25 2014-10-17 Nestec S.A. Procedimientos de diagnóstico del síndrome del intestino irritable
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CA2781654A1 (en) 2009-11-25 2011-06-03 Hua Gong Novel genomic biomarkers for irritable bowel syndrome diagnosis
SI2523688T1 (en) 2010-01-15 2018-03-30 Kirin-Amgen, Inc. Formulation of antibodies and therapeutic regimes
JP5972871B2 (ja) 2010-07-20 2016-08-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗il−23ヘテロ二量体特異的抗体
US8541180B1 (en) 2010-10-11 2013-09-24 Genova Diagnostics, Inc. Compositions and methods for assessing gastrointestinal health
KR102049223B1 (ko) 2010-11-04 2019-11-28 베링거 인겔하임 인터내셔날 게엠베하 항-il-23 항체
JP6116485B2 (ja) 2011-01-06 2017-04-19 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 心臓性突然死に関連する方法において使用するためのscn5aスプライスバリアント
EP2710383B1 (en) 2011-05-16 2017-01-11 The University of Newcastle Performance of a biomarker panel for irritable bowel syndrome
NO336551B1 (no) 2011-06-21 2015-09-28 Magne Fagerhol Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve
NO20110895A1 (no) 2011-06-21 2012-12-24 Magne Fagerhol Kompetitive S100A9 immunoanalyser
WO2013132338A2 (en) 2012-03-06 2013-09-12 Calpro As Competitive immunoassay for calprotectin
WO2013132347A2 (en) 2012-03-06 2013-09-12 Calpro As Improved elisa immunoassay for calprotectin
WO2013152114A1 (en) 2012-04-03 2013-10-10 The Regents Of The University Of Michigan Biomarker associated with irritable bowel syndrome and crohn's disease

Similar Documents

Publication Publication Date Title
JP2018535394A5 (cg-RX-API-DMAC7.html)
RU2018113694A (ru) Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23
RU2018124603A (ru) Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23
Yamamoto et al. Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases
Ha et al. Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis
JP2023508165A5 (cg-RX-API-DMAC7.html)
CN111133313A (zh) 评估生物药物治疗的受试者中的中和性抗体水平的测定及其在个性化医疗中的用途
Lee et al. Isolated anti-Ro52 identifies a severe subset of Sjögren’s syndrome patients
JP2016128441A5 (cg-RX-API-DMAC7.html)
EP3077818B1 (en) Methods for predicting post-operative recurrence of crohn's disease
CN104838270A (zh) 用于预测和监测粘膜愈合的方法
BR112016005745B1 (pt) Biomarcadores para tuberculose
Chen et al. Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis
TWI655433B (zh) 川崎氏症之診斷與治療
Fouladseresht et al. Anti-varicella zoster virus IgG and hsCRP levels correlate with progression of coronary artery atherosclerosis
Jocić et al. Interleukin 41 as a potential predictor of bio-therapy efficacy in patients with rheumatoid arthritis: A prospective observational study
Liao et al. Association of C-type lectin 18 levels with extrahepatic manifestations in chronic HCV infection
WO2015166461A1 (en) Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
Gong et al. Serum progranulin levels are elevated in patients with chronic hepatitis B virus infection, reflecting viral load
Ra et al. Kinetics of Serological Response in Patients with Severe Fever with Thrombocytopenia Syndrome. Viruses 2021, 13, 6
Kelvin Ethan B. Jansen, Ali Toloue Ostadgavahi 3, Benjamin Hewins 3, Rachelle Buchanan, Brittany M. Thivierge, Gustavo Sganzerla Martinez 3, Una Goncin 4, Magen E. Francis, Cynthia L. Swan, Erin Scruten, Jack Bell, Joseph Darbellay, Antonio Facciuolo, Darryl Falzarano, Volker Gerdts, Mark E. Fenton 6, Peter Hedlin 4, David J. Kelvin 3 &
Hussein et al. Clinical Relevance Of Anti-Cyclic Citrullinated Peptide Antibodies In Rheumatoid Arthritis
Zer et al. PVI-25 The effect of autoantibodies to test results in patients with low-titre anti-HCV positivity
Halicioglu et al. PVI-26 Hepatitis A seroprevalence in pediatric patients in west part of Turkey
Liyan et al. The relationship between IL-10 levels, gene polymorphisms and